CA2225366A1 - Substituted purine derivatives, processes for their preparation, their use, and compositions comprising them - Google Patents

Substituted purine derivatives, processes for their preparation, their use, and compositions comprising them

Info

Publication number
CA2225366A1
CA2225366A1 CA002225366A CA2225366A CA2225366A1 CA 2225366 A1 CA2225366 A1 CA 2225366A1 CA 002225366 A CA002225366 A CA 002225366A CA 2225366 A CA2225366 A CA 2225366A CA 2225366 A1 CA2225366 A1 CA 2225366A1
Authority
CA
Canada
Prior art keywords
preparation
compositions
processes
purine derivatives
substituted purine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002225366A
Other languages
French (fr)
Other versions
CA2225366C (en
Inventor
Anuschirwan Peyman
Jochen Knolle
Volkmar Wehner
Gerhard Breipohl
Jean-Francois Gourvest
Denis Carniato
Thomas Richard Gadek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Genentech Inc
Original Assignee
Hoechst Aktiengesellschaft
Anuschirwan Peyman
Jochen Knolle
Volkmar Wehner
Gerhard Breipohl
Jean-Francois Gourvest
Denis Carniato
Thomas Richard Gadek
Genentech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Aktiengesellschaft, Anuschirwan Peyman, Jochen Knolle, Volkmar Wehner, Gerhard Breipohl, Jean-Francois Gourvest, Denis Carniato, Thomas Richard Gadek, Genentech, Inc. filed Critical Hoechst Aktiengesellschaft
Publication of CA2225366A1 publication Critical patent/CA2225366A1/en
Application granted granted Critical
Publication of CA2225366C publication Critical patent/CA2225366C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

The present invention relates to compounds of the formulae I and Ia (see formula I) (see formula Ia) in which X, Y, W, W a, G and G a have the meanings given in the patent claims, and their physiologically tolerable salts and their prodrugs, their preparation, their use, in particular as pharmaceutical active compounds, and pharmaceutical preparations comprising them. The compounds of the formula I are vitronectin receptor antagonists and can be employed, for example, as inhibitors of bone resorption and for the treatment of osteoporosis.
CA002225366A 1996-12-20 1997-12-19 Substituted purine derivatives, processes for their preparation, their use, and compositions comprising them Expired - Lifetime CA2225366C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19653646.4 1996-12-20
DE19653646A DE19653646A1 (en) 1996-12-20 1996-12-20 Substituted purine derivatives, processes for their preparation, agents containing them and their use

Publications (2)

Publication Number Publication Date
CA2225366A1 true CA2225366A1 (en) 1998-06-20
CA2225366C CA2225366C (en) 2006-10-10

Family

ID=7815761

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002225366A Expired - Lifetime CA2225366C (en) 1996-12-20 1997-12-19 Substituted purine derivatives, processes for their preparation, their use, and compositions comprising them

Country Status (22)

Country Link
EP (1) EP0853084B1 (en)
JP (1) JP4620190B2 (en)
KR (1) KR19980064655A (en)
CN (2) CN1101816C (en)
AR (1) AR010700A1 (en)
AT (1) ATE404562T1 (en)
AU (1) AU728865B2 (en)
BR (1) BR9706387A (en)
CA (1) CA2225366C (en)
CZ (1) CZ294437B6 (en)
DE (2) DE19653646A1 (en)
HK (1) HK1012190A1 (en)
HU (1) HUP9702507A3 (en)
ID (1) ID19254A (en)
IL (1) IL122642A0 (en)
NO (1) NO314583B1 (en)
NZ (1) NZ329431A (en)
PL (1) PL323969A1 (en)
RU (1) RU2228335C2 (en)
TR (1) TR199701647A2 (en)
TW (1) TW523515B (en)
ZA (1) ZA9711317B (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6284764B1 (en) 1999-01-27 2001-09-04 Pfizer Inc. Substituted bicyclic derivatives useful as anticancer agents
US6465449B1 (en) 1999-01-27 2002-10-15 Pfizer Inc. Heteroaromatic bicyclic derivatives useful as anticancer agents
US8133896B2 (en) 2004-05-18 2012-03-13 Galapagos Nv Pyrimidine derivatives which are antagonist of the vitronectin receptor

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1074543B1 (en) 1998-04-09 2012-01-25 Meiji Seika Pharma Co., Ltd. Aminopiperidine derivatives as integrin alpha v beta 3 antagonists
CA2356748A1 (en) 1998-12-23 2000-07-06 G.D. Searle & Co. Method of using an integrin antagonist and radiation therapy as combination therapy in the treatment of neoplasia
EP1065208A1 (en) * 1999-07-02 2001-01-03 Aventis Pharma Deutschland GmbH Substituted purine derivatives as inhibitors of cell adhesion
EP1065207A1 (en) 1999-07-02 2001-01-03 Aventis Pharma Deutschland GmbH Naphthyridine derivatives, processes for their preparation, their use, and pharmaceutical compositions comprising them
AU6316900A (en) 1999-08-05 2001-03-05 Meiji Seika Kaisha Ltd. Omega-amino-alpha-hydroxycarboxylic acid derivatives having integrin alphavbeta3antagonism
EP1176145A1 (en) * 2000-07-28 2002-01-30 Aventis Pharma Deutschland GmbH Novel guanidino derivatives as inhibitors of cell adhesion
DE10042655A1 (en) 2000-08-31 2002-03-14 Aventis Pharma Gmbh Process for the preparation of inhibitors of cell adhesion
KR100438820B1 (en) * 2001-03-05 2004-07-05 삼성코닝 주식회사 Method for manufacturing compound semiconductor substrate of III-V group
AU2002316855B2 (en) 2001-04-24 2008-03-13 Merck Patent Gmbh Combination therapy using anti-angiogenic agents and TNFalpha
FR2847254B1 (en) * 2002-11-19 2005-01-28 Aventis Pharma Sa NOVEL VITRONECTIN RECEPTOR ANTAGONIST DERIVATIVES, PROCESS FOR PREPARING THEM, THEIR APPLICATION AS MEDICAMENTS AND THE PHARMACEUTICAL COMPOSITIONS REFLECTING THEM
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
CA2637387A1 (en) 2006-01-18 2007-07-26 Simon Goodman Specific therapy using integrin ligands for treating cancer
WO2008087025A2 (en) 2007-01-18 2008-07-24 Merck Patent Gmbh Specific therapy and medicament using integrin ligands for treating cancer
DK2206727T3 (en) 2007-10-11 2015-07-06 Daiichi Sankyo Co Ltd ANTIBODY SPECIFIC TO OSTEOKLASTRELATERET PROTEIN Siglec-15
JP2011503206A (en) * 2007-11-14 2011-01-27 ミレクシス， インコーポレイテッド Therapeutic compounds and methods of use thereof in the treatment of diseases and disorders
AU2010235453B2 (en) 2009-04-09 2013-10-03 Daiichi Sankyo Company,Limited Anti-Siglec-15 antibody
US20120130146A1 (en) 2009-05-25 2012-05-24 Merck Patent Gmbh Continuous administration of cilengitide in cancer treatments
EP2625205A2 (en) 2010-10-05 2013-08-14 Daiichi Sankyo Company, Limited Antibody targeting osteoclast-related protein siglec-15
SG11201405966PA (en) 2012-03-30 2014-11-27 Daiichi Sankyo Co Ltd Cdr-modified anti-siglec-15 antibody
CN103665043B (en) 2012-08-30 2017-11-10 江苏豪森药业集团有限公司 A kind of tenofovir prodrug and its application in medicine
RU2016146826A (en) 2014-05-30 2018-07-04 Пфайзер Инк. CARBONITRIL DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4730696Y1 (en) * 1966-12-10 1972-09-13
JPS6396663A (en) * 1986-10-13 1988-04-27 Mita Ind Co Ltd Electrostatic charge image developing toner
JPS6396553A (en) * 1986-10-14 1988-04-27 Sekisui Chem Co Ltd Packing material
DE4129603A1 (en) * 1991-09-06 1993-03-11 Thomae Gmbh Dr K CONDENSED 5-LOW HETEROCYCLES, METHOD FOR THE PRODUCTION THEREOF, AND MEDICAMENTS CONTAINING THESE COMPOUNDS
MX9207334A (en) * 1991-12-18 1993-08-01 Glaxo Inc NUCLEIC ACIDS PEPTIDICS AND PHARMACEUTICAL FORMULATION CONTAINING THEM
FR2700337B1 (en) * 1993-01-11 1995-04-14 Lafon Labor Imidazopyridine-2-one derivatives, their preparation process and their use in therapy.
US6133444A (en) * 1993-12-22 2000-10-17 Perseptive Biosystems, Inc. Synthons for the synthesis and deprotection of peptide nucleic acids under mild conditions
DE4405378A1 (en) * 1994-02-19 1995-08-24 Merck Patent Gmbh Adhesion receptor antagonists
US5554746A (en) * 1994-05-16 1996-09-10 Isis Pharmaceuticals, Inc. Lactam nucleic acids
US5929046A (en) * 1994-06-08 1999-07-27 Cancer Research Campaign Technology Limited Pyrimidine and purine derivatives and their use in treating tumour cells
US6110923A (en) * 1994-06-22 2000-08-29 Biochem Pharma Inc. Method for treating cancer using novel substituted purinyl derivatives with immunomodulating activity
JPH10504808A (en) * 1994-06-29 1998-05-12 スミスクライン・ビーチャム・コーポレイション Vitronectin receptor antagonist
US5525606A (en) * 1994-08-01 1996-06-11 The United States Of America As Represented By The Department Of Health And Human Services Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines
WO1996020212A2 (en) * 1994-12-28 1996-07-04 Buchardt, Dorte Peptide nucleic acid incorporating a chiral backbone
US5977061A (en) * 1995-04-21 1999-11-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic N6 - substituted nucleotide analagues and their use
JP2001518054A (en) * 1995-06-07 2001-10-09 パーセプティブ バイオシステムズ，インコーポレーテッド PNA-DNA chimera and PNA synthon for chimera synthesis
JPH1025294A (en) * 1996-03-26 1998-01-27 Akira Matsuda Condensed heterocyclic derivative, its production and malignant tumor therapeutic agent containing the same
EP0901476A4 (en) * 1996-03-26 2001-08-16 Du Pont Pharm Co Aryloxy- and arylthio-fused pyridines and pyrimidines and derivatives
GB9613021D0 (en) * 1996-06-21 1996-08-28 Pharmacia Spa Bicyclic 4-aralkylaminopyrimidine derivatives as tyrosine kinase inhibitors
DE69734783T2 (en) * 1996-07-24 2006-08-17 Buchardt, Dorte PEPTID NUCLEIC ACIDS WITH INCREASED BINDING SAFFINITY, SEQUENCE SPECIFICITY AND SOLUBILITY
US5866702A (en) * 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6284764B1 (en) 1999-01-27 2001-09-04 Pfizer Inc. Substituted bicyclic derivatives useful as anticancer agents
US6465449B1 (en) 1999-01-27 2002-10-15 Pfizer Inc. Heteroaromatic bicyclic derivatives useful as anticancer agents
US6541481B2 (en) 1999-01-27 2003-04-01 Pfizer Inc Substituted bicyclic derivatives useful as anticancer agents
US6867201B2 (en) 1999-01-27 2005-03-15 Pfizer Inc Heteroaromatic bicyclic derivatives useful as anticancer agents
US8133896B2 (en) 2004-05-18 2012-03-13 Galapagos Nv Pyrimidine derivatives which are antagonist of the vitronectin receptor
US8765766B2 (en) 2004-05-18 2014-07-01 Galapagos Nv Pyrimidine derivatives which are antagonists of the vitronectin receptor

Also Published As

Publication number Publication date
CA2225366C (en) 2006-10-10
CZ411497A3 (en) 1998-07-15
HUP9702507A2 (en) 1999-05-28
AU4846697A (en) 1998-06-25
NO314583B1 (en) 2003-04-14
JP4620190B2 (en) 2011-01-26
BR9706387A (en) 2000-03-14
DE19653646A1 (en) 1998-06-25
NO975977L (en) 1998-06-22
AR010700A1 (en) 2000-06-28
AU728865B2 (en) 2001-01-18
NO975977D0 (en) 1997-12-19
ID19254A (en) 1998-06-28
TR199701647A3 (en) 1998-07-21
NZ329431A (en) 2000-01-28
HU9702507D0 (en) 1998-03-02
EP0853084A2 (en) 1998-07-15
HUP9702507A3 (en) 1999-12-28
KR19980064655A (en) 1998-10-07
CN1101816C (en) 2003-02-19
TR199701647A2 (en) 1998-07-21
ZA9711317B (en) 1998-06-22
MX9710277A (en) 1998-10-31
EP0853084A3 (en) 1998-09-09
CZ294437B6 (en) 2005-01-12
JPH10182645A (en) 1998-07-07
HK1012190A1 (en) 1999-07-30
TW523515B (en) 2003-03-11
PL323969A1 (en) 1998-06-22
IL122642A0 (en) 1998-08-16
DE59712958D1 (en) 2008-09-25
ATE404562T1 (en) 2008-08-15
CN1495184A (en) 2004-05-12
CN1193623A (en) 1998-09-23
RU2228335C2 (en) 2004-05-10
EP0853084B1 (en) 2008-08-13

Similar Documents

Publication Publication Date Title
CA2225366A1 (en) Substituted purine derivatives, processes for their preparation, their use, and compositions comprising them
AP2000001842A0 (en) Novel acylguanidine derivatives as inhibitors of bone resorption and as vitronectin receptor antagonists.
BG104630A (en) Novel sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion
CA2211270A1 (en) Novel cycloalkyl derivatives as inhibitors of bone resorption and vitronectin receptor antagonists
IL150986A0 (en) 1,2,3,4,- tetrahydroisoquinoline derivatives
MY120842A (en) 1,4-benzothiazepine-1, 1-dioxide derivatives substituted by sugar residues, process for their preparation, pharmaceuticals comprising these compounds, and their use.
WO2003037860A3 (en) Purine analogs having hsp90-inhibiting activity
MY128014A (en) Thiol and thiocarbonyl derivatives which are useful as carboxypeptidase u inhibitors
CA2371789A1 (en) Novel guanidine derivatives as inhibitors of cell adhesion
MY114944A (en) Propanolamine derivatives, processes for their preparation pharmaceuticals comprising these compounds, and their use
IL145564A0 (en) Substituted 1,4-dihydroindeno [1,2-c] pyrazoles as inhibitors of tyrosine kinase
EP1019047A4 (en) Antithrombotic agents
HUP0104804A2 (en) Tetrahydro-naphthyridinyl derivative as vitronectin receptor antagonist, process for its preparation and pharmaceutical composition containing the same
HK1053109A1 (en) Substituted homopiperidinyl benzimidazole compounds, pharmaceutical compositions comprising the same, methods for preparing them and the use for the preparation of a medicament of them
HUP0202710A2 (en) Vitronectin receptor antagonists, pharmaceutical compositions containing them and their use
CA2376668A1 (en) Naphthyridine derivatives, processes for their preparation, their use and pharmaceutical compositions comprising them
EP1027051A4 (en) Antithrombotic agents
DE69927997D1 (en) Novel pyrimidine derivatives and method for their preparation
YU89701A (en) Substituted purine derivatives as inhibitors of cell adhesion
ZA935045B (en) Pharmacologically active alfa-(tertiary-aminomethyl)-ben-zenemethanol derivatives
HUP0401912A3 (en) Pharmaceutically acceptable salts of 20(s)-camptothecins, process for their preparation and pharmaceutical compositions containing them
MY132635A (en) Cycloalkyl derivatives as inhibitors of bone resporption and vitronectin receptor antagonists
DE69824410D1 (en) Antithrombosemittel
AU2001278503A1 (en) Novel guanidino derivatives as inhibitors of cell adhesion
IL141218A0 (en) Alendronic acid, pharmaceutically acceptable salts thereof or mixtures thereof, for use as a medicament or for use in the manufacture of a medicament, pharmaceutical compositions and kits comprising any of thereof, all for inhibiting bone resorption

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20171219